Receive The Newest Study Notifications

-- Orally administered PRN2246 achieved full BTK occupancy in peripheral blood -- -- PRN2246 exhibited blood-brain barrier permeability and CNS exposure -- -- Sanofi to lead Phase 2 development for people with Multiple Sclerosis -- SOUTH SAN FRANCISCO, Calif., March...

-Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim results from its Phase 2 clinical trial evaluating its product candidate CTP-543 in patients with moderate-to-severe alopecia areata will be presented in an oral presentation during the...

Testing Potential Treatment for Lupus The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a...

Completion of enrollment of both monotherapy and dual combination dose escalation arms expected in 2019 Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical...

Aesculap Biologics, LLC ("Aesculap Biologics") announced today that it has successfully achieved 50 percent enrollment in the ongoing Phase 3 clinical trial of NOVOCART® 3D, an autologous chondrocyte transplantation system designed to treat articular cartilage defects...

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American Association for Cancer...

Trovagene, Inc. (Nasdaq:  TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that two...

Phase 3 Results from ALLEVIATE Trial in Allergic Conjunctivitis Expected in Early 2019 Co-Primary Endpoints Confirmed for Phase 3 Clinical Trial in Dry Eye Disease, Expected to Begin in First Half of 2019 Phase 3 Clinical Trial of ADX-2191 in Proliferative...

Critical Path Institute's (C-Path) Data Collaboration Center (DCC) and the Friedreich's Ataxia Research Alliance (FARA) today announced the launch of the Friedreich's Ataxia Integrated Clinical Database (FAICD). The new platform will enable collaborative research and...

Natreon's Patented PrimaVie® (Shilajit) Promoted the Retention of Muscular Strength and a Decrease in Hydroxyproline (a marker of collagen degradation) in a Recently Published Clinical Trial at The University of Nebraska-Lincoln. Natreon, a leader in Ayurvedic...

Hound Labs, Inc., a leader in the field of breath diagnostics, today announced results of its second clinical trial with the University of California, San Francisco (UCSF), in which researchers measured THC 1 in breath. Results from this landmark study confirm – for...

Company aims to be ready to launch the trial in Q2-2019 NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it has filed the clinical...

Stero Biotechs has received Ethics Committee approval by Israel'sMinistry of Health and will soon enroll the first patients in a ground-breaking study to use CBD to reduce steroids in patients with liver disease. Stero discovered that by introducing CBD to patients...

 NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin, has been accepted for poster presentation at the...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first patient has been dosed in ORIENT-32, a trial that evaluates Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal...

LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of...

Company’s lead product candidate previously demonstrated positive top-line results from the diffuse large B-cell lymphoma cohort of this study Dosing in multiple tumor types is ongoing; Cellectar intends to report additional data this year Cellectar Biosciences, Inc....

Protocol design can have a significant impact on patient engagement and clinical trial performance. In this live webinar, explore the findings of a recent scholarly study conducted by the Center for the Study of Drug Development (CSDD) at Tufts University School of...

Phase III POLO Trial Met Primary Endpoint of Progression-Free Survival AstraZeneca and Merck’s LYNPARZA is the first PARP inhibitor to demonstrate benefit in gBRCAm metastatic pancreatic cancer in a Phase III Trial   AstraZeneca and Merck & Co., Inc.,...

Appointment of Shashank Mahashabde as VP of CMC and Pablo Jimenez, MD FAPCR as VP and Therapeutic Area Head of Immunology Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of innovative medicines in...